Recently, Jiang et al
It does not carry the gastrointestinal or renal risks associated with NSAIDs and has no known interaction with semaglutide
This functional improvement is accompanied by significant reductions in the core AD pathologies
Together, these trials involved 861 adults, mainly from Asia, North Africa, and the Middle East

The Effect Of Berberine Supplementation On Obesity Parameters, Inflammation And Liver Function Enzymes: A Systematic Review And Meta-Analysis Of Randomized Controlled Trials (April 25, 2020) Berberine and Weight Loss: What You Need To Know (November 2023) Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials (April 26, 2021) Berberine in the Treatment of Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis (October 15, 2012) Berberine for Appetite Suppressant and Prevention of Obesity (December 12, 2020) Effects Of Administering Berberine Alone Or In Combination On Type 2 Diabetes Mellitus: A Systematic Review And Meta-Analysis (November 21, 2024) Two-Year Effects Of Semaglutide In Adults With Overweight Or Obesity: The Step 5 Trial (October 10, 2022) Tirzepatide Once Weekly for the Treatment of Obesity (June 4, 2022)

Especially in patients who already suffer from gastroesophageal reflux disease (GERD), these side effects can aggravate symptoms